AMS Q3 Earnings Preview: Testing the Resilience of Shared Oncology Financing

SAN FRANCISCO, CA – November 09, 2026 – At a time when regional health systems are starved for capital, the business of treating cancer has never been more technologically advanced—or more financially precarious. American Shared Hospital Services (NYSE American: AMS), a leading provider of stereotactic radiosurgery equipment and advanced radiation therapy, announced today that it will release its third-quarter 2026 financial results before the market opens on November 12, 2026. The release will be followed by an executive conference call and simultaneous webcast at 12:00 p.m. ET to discuss the company's operational and financial performance.

For healthcare equity investors and hospital administrators alike, the upcoming earnings call represents far more than a routine quarterly update. It serves as a real-time stress test of a unique joint-venture financing structure designed to provide regional hospitals with an alternative to the outright purchase of multi-million-dollar oncology equipment. As macroeconomic pressures mount and Medicare reimbursement policies undergo seismic shifts, AMS finds itself at the intersection of booming clinical demand and tightening financial constraints.

Decentralizing Advanced Cancer Care: The Turnkey Solution

The core proposition of American Shared Hospital Services lies in its shared-ownership model. The company provides turnkey solutions to cancer treatment centers and health systems across North and South America, supplying complex technologies like the Leksell Gamma Knife and Proton Beam Radiation Therapy (PBRT) systems. By sharing the capital investment costs and operating margins with healthcare network partners, AMS effectively lowers the barrier to entry for community hospitals looking to offer top-tier oncology services close to patients' homes.

Recent quarters have shown the clinical viability of this strategy. In the first half of 2026, the company reported a material increase in its direct patient care services. The second quarter saw total revenue increase 19% year-over-year to $8.4 million, driven by a 40% surge in direct patient services revenue. This growth was fueled by higher procedure volumes at the company's Rhode Island radiation therapy centers, as well as its international facilities in Peru and Puebla, Mexico. Furthermore, a recent lease extension with Orlando Health for PBRT services through April 2033 underscores the long-term reliance health systems place on these strategic partnerships.

However, the strategy of decentralizing complex cancer care is not without its operational friction. While procedure volumes for PBRT and Gamma Knife treatments have increased, the cost of maintaining and expanding this footprint is significant, leading to a complex financial picture that investors will be eager to dissect on Thursday's call.

Navigating the Medicare Reimbursement Squeeze

The most pressing systemic challenge facing AMS and its hospital partners is the rapidly evolving landscape of federal reimbursement. The Centers for Medicare & Medicaid Services (CMS) has introduced significant modifications impacting radiation oncology, creating a volatile environment for both equipment lessors and direct care providers.

For calendar year 2026, CMS finalized a 2.6% increase to the Hospital Outpatient Prospective Payment System (HOPPS) fee schedule. However, the reality on the ground for physicians is far less optimistic. New treatment delivery codes and image guidance codes took effect in January 2026, with the technical component of image guidance now bundled into the reimbursement for updated delivery codes. While CMS estimated a marginal 1% negative impact overall for radiation oncology, industry surveys paint a much bleaker picture. According to the American Society for Radiation Oncology (ASTRO), over two-thirds of physicians reported double-digit reimbursement declines this year, a financial shockwave that has triggered clinic closures, layoffs, and intense consolidation pressure across the sector. Reimbursement for Intensity-Modulated Radiation Therapy (IMRT) for prostate cancer, a highly common procedure, has plummeted by 14%.

Looking ahead, the regulatory horizon presents even more profound changes. Under the proposed rules for 2027, CMS plans to establish a single national rate for proton therapy, replacing a patchwork of regional Medicare contractor rates that previously allowed for significant regional variability. Crucially, under these new national rates, freestanding proton centers will be paid approximately 23% below the hospital rate for the exact same treatment. The National Association for Proton Therapy has voiced deep concerns that this methodology significantly undervalues the specialized nature of PBRT. For AMS, which operates across both hospital-affiliated and freestanding models, management's commentary on navigating this 2027 rate shock will be a critical focal point for analysts.

Debt Covenants and Capital Restructuring

Beyond external regulatory pressures, AMS is navigating internal financial complexities. Despite the impressive top-line revenue growth reported in Q2 2026, the company posted a net loss of $514,000, or $0.07 per diluted share, widening from a net loss of $280,000 in the same period the previous year. This loss was heavily influenced by $285,000 in legal fees associated with a credit agreement amendment and a $909,000 increase in credit allowances for its Rhode Island facilities.

Liquidity and debt management remain paramount. While cash and cash equivalents improved to $6.8 million by mid-2026, the company is operating under the constraints of an amended credit agreement with Fifth Third Bank. With approximately $13.3 million of debt maturing in June 2027, management is actively pursuing refinancing options. The stakes are high; the amended agreement notably requires the company to pursue a sale of all or part of its assets.

Recent maneuvers indicate a proactive, if urgent, approach to shoring up the balance sheet. Following the second quarter, a company formed by Executive Chairman Ray Stachowiak injected $2 million of subordinated financing. Additionally, a July 2026 forbearance agreement introduced another $2 million note and warrant. Investors tuning into the November 12 webcast will be listening closely for updates from leadership—including the investor relations team at PCG Advisory—on the progress of refinancing efforts and the long-term viability of the current capital structure.

Industry Tailwinds Amidst Macro Headwinds

Despite the immediate financial and regulatory hurdles, the broader macroeconomic backdrop for oncology devices remains robust. The global oncology device market, valued at nearly $79 billion in 2024, is projected to exceed $152 billion by 2035. Radiation therapy accounts for roughly 36% of this massive market, driven by an aging global population, a rising cancer burden, and a continuous push toward precision medicine.

Yet, capturing this growth is proving difficult even for industry giants. Peer companies like Elekta recently reported mixed financial results, experiencing a 14% stock drop after announcing a 1% year-over-year decrease in net sales and initiating restructuring efforts aimed at securing over SEK 500 million in cost savings. Siemens Healthineers and other major players are similarly navigating the complexities of hospital capital expenditure slowdowns. If multi-billion-dollar manufacturers are feeling the pinch of foreign exchange headwinds and shifting capital equipment demand, smaller, specialized players like AMS must rely heavily on the agility of their business models.

The dichotomy of the modern healthcare sector is fully on display with American Shared Hospital Services. The clinical demand for advanced, localized cancer treatment is undeniable, and the turnkey leasing model offers a logical solution for cash-strapped hospitals. Whether the company can successfully thread the needle between tightening Medicare reimbursements and its own debt restructuring obligations will be the defining narrative of the upcoming earnings call.